Goldman Sachs’s Provention Bio PRVB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
– Sell
-864,081
Closed -$20.8M – 6274
2023
Q1
$20.8M Buy
864,081
+644,811
+294% +$8.09M ﹤0.01% 1785
2022
Q4
$2.32M Sell
219,270
-6,053
-3% -$48.8K ﹤0.01% 3833
2022
Q3
$1.01M Sell
225,323
-116,388
-34% -$530K ﹤0.01% 4496
2022
Q2
$1.37M Buy
341,711
+98,020
+40% +$465K ﹤0.01% 4380
2022
Q1
$1.78M Sell
243,691
-25,889
-10% -$155K ﹤0.01% 4352
2021
Q4
$1.52M Buy
269,580
+60,343
+29% +$383K ﹤0.01% 4486
2021
Q3
$1.34M Sell
209,237
-123,363
-37% -$793K ﹤0.01% 4525
2021
Q2
$2.8M Sell
332,600
-7,906
-2% -$63.8K ﹤0.01% 3895
2021
Q1
$3.57M Buy
340,506
+267,517
+367% +$3.76M ﹤0.01% 3449
2020
Q4
$1.24M Sell
72,989
-60,928
-45% -$913K ﹤0.01% 4060
2020
Q3
$1.72M Buy
133,917
+27,302
+26% +$345K ﹤0.01% 3675
2020
Q2
$1.5M Buy
106,615
+2,375
+2% +$30K ﹤0.01% 3655
2020
Q1
$959K Buy
+104,240
New +$1.34M ﹤0.01% 3794
2019
Q2
– Sell
-15,727
Closed -$36K – 5418
2019
Q1
$36K Sell
15,727
-4,008
-20% -$9.41K ﹤0.01% 5023
2018
Q4
$35K Sell
19,735
-2,165
-10% -$6.22K ﹤0.01% 5118
2018
Q3
$88K Buy
+21,900
New +$86.6K ﹤0.01% 5180

Other funds holding PRVB

Goldman Sachs's PRVB Position: Q2 2023 in Review

Goldman Sachs sold out of Provention Bio (PRVB) in Q2 2023, closing a stake of 864,081 shares — an estimated $20.8M sold.

Goldman Sachs first reported a position in PRVB in Q3 2018 and held it in 16 quarters. The position peaked at $20.8M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

  • Goldman Sachs reported no remaining Provention Bio position as of Q2 2023 after selling out during the quarter.
  • Goldman Sachs sold 864,081 Provention Bio shares in Q2 2023, an estimated $20.8M.
  • Goldman Sachs first reported a position in Provention Bio in Q3 2018 and held it in 16 quarters.
  • Goldman Sachs's Provention Bio position peaked at $20.8M in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Provention Bio as of Q2 2023.

Based on Goldman Sachs's 13F filing for Q2 2023, filed 15 Aug 2023.